Abstract

Private insurance plays a minor role in paying for pharmaceuticals in New Zealand, despite controversy about access through the public health system. The present study examines New Zealand consumers’ perceptions of private insurance for pharmaceuticals. A self-administered questionnaire was completed by 433 consumers at thirty pharmacies. The questionnaire included 18 questions on demographics, insurance status, perceptions of private insurance for pharmaceuticals and confidence in the public health system. Forty six percent of respondents had private health insurance. Respondents were more likely to have private health insurance as household income increased, and confidence in the public health system decreased. (Over two thirds of respondents were either confident or very confident in the public health system). Nineteen percent had private health insurance for pharmaceuticals, and the likelihood was not affected by household income or confidence in the public health system. Sixty one percent believed private insurance for pharmaceuticals would increase availability and affordability of pharmaceuticals. However, just over half were willing to pay for private insurance for pharmaceuticals. Of these, over two thirds were only willing to pay $20 per year or less. New Zealand pharmacy consumers’ willingness to pay for private insurance for pharmaceuticals is very low.

Highlights

  • Private insurance pays for a mere 2% of pharmaceutical costs in New Zealand (The Organisation for Economic Co-operation and Development 2010a)

  • Private insurance pays for 17% of outpatient pharmaceutical costs in France, and 30% in Canada and the United States (The Organisation for Economic Co-operation and Development 2010b)

  • The number of visits to a pharmacy, average monthly spends at a pharmacy, or whether patients were on medicines that weren’t publically funded had no effect on whether respondents had private insurance

Read more

Summary

Introduction

Private insurance pays for a mere 2% of pharmaceutical costs in New Zealand (The Organisation for Economic Co-operation and Development 2010a). Private insurance pays for 17% of outpatient pharmaceutical costs in France, and 30% in Canada and the United States (The Organisation for Economic Co-operation and Development 2010b). New Zealand’s per capita pharmaceutical expenditure is lower than such countries. In 2010 this was 288 United States Dollars Purchasing Power Parity (US$ PPP), compared with 637 US$ PPP in France, 739 US$ PPP in Canada and 973 US$ PPP in the United States (The Organisation for Economic Co-operation and Development 2013). New Zealanders pay for approximately 30% of pharmaceutical costs out-of-pocket, a figure which includes prescription charges, prescription medicines that are not publically funded, and non-prescription medicines. The proportion of out-of-pocket spending in New Zealand is

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call